Meeting
2018 Gastrointestinal Cancers Symposium
Is there a role for histology based treatment choice in advanced gastric cancer (GC)?
Authors
Rosalba Barile
Humanitas Gavazzeni, Bergamo, Italy
Rosalba Barile , Michela Squadroni , Federica Brena , Eleonora Cerchiaro , Valeria Zurlo , Giordano D. Beretta
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Cancers of the Esophagus and Stomach
Track
Cancers of the Esophagus and Stomach
Sub Track
Multidisciplinary Treatment
Citation
J Clin Oncol 36, 2018 (suppl 4S; abstr 135)
DOI
10.1200/JCO.2018.36.4_suppl.135
Abstract #
135
Poster Bd #
J16
Abstract Disclosures
Similar Posters
Poster
2015 Gastrointestinal Cancers Symposium
Lapatinib combined with ECF/x as first-line metastatic gastric cancer (GC) according to HER2 and EGFR status: A randomized placebo controlled phase II (EORTC 40071).
First Author: Markus Hermann Moehler
Poster
2024 ASCO Gastrointestinal Cancers Symposium
Tislelizumab combined with POFI (irinotecan, paclitaxel, oxaliplatin and 5-FU/levoleucovorin) as first-line treatment of advanced gastric/gastroesophageal junction adenocarcinoma (AGC): Preliminary results of a single-arm, open-label phase I/II trial (SYLT-023).
First Author: Rongbo Lin
Poster
2021 ASCO Annual Meeting
Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Keun Wook Lee
Poster
2020 ASCO Virtual Scientific Program
ZW25, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.
First Author: Do-Youn Oh